Regular purchasing channels for Elotuzumab

Elotuzumab (Elotuzumab) is an immunotherapy drug that belongs to the monoclonal antibody class and is mainly used to treat multiple myeloma (MM). Although the drug has been approved and marketed in overseas markets, it has not been officially approved for marketing in China. Therefore, there are currently no formal purchasing channels in China and no specific price information. For domestic patients, evolizumab cannot yet be reimbursed by medical insurance or purchased directly.

In overseas markets, the price of evolizumab is usually higher, especially the European version of the original drug. In Europe, the price of each box of 300 mg evolizumab is approximately RMB 15,000 (the price may fluctuate due to exchange rate fluctuations). This price reflects its high production and research and development costs, especially when there are currently no generic drugs on the market, and the price of the original drug has become an important consideration for patients when obtaining the drug.

Currently, since evolizumab has not yet been marketed in China, patients who wish to use the drug can usually only obtain the drug through "overseas drug purchase" or through clinical trials at medical institutions. However, these avenues carry certain legal and regulatory risks, so patients should exercise extreme caution and under the guidance of a physician when trying these approaches.

With the continuous accumulation of drug clinical data, it is more likely that evolizumab will be launched in the Chinese market in the future. By then, the purchasing channels and price information of the drug will be clearer, and patients can also obtain the drug through formal channels. Prior to this, patients need to pay attention to the development of the drug and maintain communication with their doctors in order to obtain the latest information on treatment in a timely manner.

Reference materials:https://www.empliciti.com/